TITLE

A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)

AUTHOR(S)
Nagpal, Manish; Nagpal, Kamal; Nagpal, P. N.
PUB. DATE
November 2007
SOURCE
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p437
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Wet age-related macular degeneration and diabetic retinopathy are pathological consequences of vascular endothelial growth factor (VEGF) release as a reaction to deficiency of oxygen and nutrients in the macular cells. Conventional treatment modalities have been constrained by limited success. Convincing evidence exists that targeting VEGF signaling is a significant approach for the therapy of these ocular angiogenesis-dependent disorders. We have come a long way since the approval of the first angiogenesis inhibitors in medicine. The clinical use of these drugs has provided enormous tempo to clinical and pharmacological research. It has also significantly altered patient outcome and expectations. In the following brief, we will discuss the development and emergence of these drugs as well as the anticipated future course based on evidence.
ACCESSION #
27260100

 

Related Articles

  • Anti-VEGF monotherapy more cost-effective in treating diabetic macular edema. Regillo, Carl D. // Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, Special section p12 

    The article discusses a study which finds that anti-vascular endothelial growth factor (VEGF) monotherapy (ranibizumab) is more cost-effective than laser photocoagulation monotherapy to treat diabetic macular edema while the cost-effectiveness of combined therapy is uncertain.

  • Comparison studies of anti-VEGF agents a 'global effort'. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.

  • Sonepcizumab, anti-VEGF may yield long-term visual acuity. Charters, Lynda // Ophthalmology Times;11/15/2016, Vol. 41 Issue 19, p26 

    The article reports on the Nexus Study on the monoclonal antibody sonepcizumab and its effect of improving visual acuity and potential for long-term stabilization for patients diagnosed with age-related macular degeneration (AMD). Topics include the efficacy of sonepcizumab monotherapy and in...

  • Anti-VEGF injections may not be preferred for AMD patients with poor baseline visual acuity. Pagnani, Michelle // Ocular Surgery News;3/25/2012, Vol. 30 Issue 6, p10 

    The article reports on a study which found that for those with age-related macular degeneration and poor baseline acuity, consideration of an alternative to anti-vascular epithelial growth factor (VEGF) therapy may be warranted.

  • Silicone deposits in repackaged anti-VEGF may cause permanent IOP spikes. Kahook, Malik Y. // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p15 

    The article focuses on the occurrence of intraocular pressure (IOP) spikes of patients that receive intravitreal injections, wherein it is said that IOP spikes is due to the silicone oil deposits that leach from the repackage vials of anti-vascular endothelial growth factor (VEGF) agents.

  • Anti-VEGF patterns of use may vary for DME cases in clinical practice. Harrison, Laird // Ophthalmology Times;Sep2015, Vol. 40 Issue 15, p70 

    The article presents the results of a study on the effectiveness of anti-vascular endothelial growth factor (VEGF) treatments for diabetic macular edema conducted by Dr. Kevin Blinder at Washington University in St. Louis, Missouri. Topics mentioned include disappointing results in clinical...

  • Clinical Diagnosis. Managing retinal vaso-occlusive diseases. Groves, Nancy; Suñer, Ivan J. // Ophthalmology Times;10/15/2014, Vol. 39 Issue 19, p36 

    The article reviews a study that determined the effectivity of ranibizumab injection through an ultra-widefield fluorescein angiography-guided injection for branch retinal vein occlusion (BRVO) in patients with macular edema. Topics covered include ranibizumab blocking vascular endothelial...

  • Age-related macular degeneration. Ong, B. B.; Ah-Fat, F. G. // British Journal of Hospital Medicine (17508460);Feb2016, Vol. 77 Issue 2, pC18 

    The article discusses clinical information on age-related macular degeneration (AMD). Topics explored include the percentage of visual impairment cases in Great Britain which may be attributed to AMD, pathophysiological factors which characterize geographic atrophy and exudative AMD, and...

  • Combining anti-PDGF with anti-VEGF may improve visual acuity, reduce AMD treatment burden.  // Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, Special section p1 

    The article states that the complex disease process 'Advanced age-related macular degeneration be treated by modulating two factors 'VEGF' and 'PDGF'.When anti VEGF therapy is combined with anti platelet derived growth factor aptamer it leads to a better visual outcome.The limitation of anti...

  • Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. Lyseng-Williamson, Katherine; Frampton, James // Drugs & Therapy Perspectives;Sep2013, Vol. 29 Issue 9, p268 

    Ranibizumab (Lucentis), an inhibitor of multiple vascular endothelial growth factor A isoforms, is approved for the intravitreal treatment of neovascular (wet) age-related macular degeneration (AMD). In clinical trials in patients with neovascular AMD, monthly or less frequent injections of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics